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Abstract
Background/Aim. Bleeding from peptic ulcers can be ef-
fectively and safely treated with endoscopic hemoclips ther-
apy. However, due to certain limiting factors of hemoclips,
application of combination with another endoscopic
method may give better results. The aim of this study was to
examine the efficacy and safety of endoscopic hemoclips
therapy and to evaluate potential benefits of this therapy
combined with epinephrine in the treatment of bleeding
peptic ulcers. Methods. This prospective randomized study
included 70 patients with bleeding gastric or duodenal ulcer.
In 34 of the patients endoscopic hemoclips therapy was ap-
plied (group I), and in 36 of them a combined therapy of
hemoclips and epinephrine (group II). Results. Initial he-
mostasis was achieved in most patients treated with endo-
scopic hemoclips therapy (94.1%) as well as in the patients
treated with combination therapy (97.2%). After initial he-
mostasis achieved rebleeding occurred in 3 (9.3%) patients
treated with hemoclips and in 2 (5.7%) patients treated with
combination therapy, but this difference was not statistically
significant (p > 0.05). The difference in the achieved final
hemostasis between the group I (91.1%) and the group II
(94.4%) was not statistically significant. Also, the differences
between the two groups of patients in the need for blood
transfusions, length of hospital stay, need for surgery and
mortality were not statistically significant (p > 0.05). Con-
clusion. Endoscopic hemoclips therapy is effective and safe
in treatment of bleeding peptic ulcers. Combination therapy
of hemoclips and epinephrine has no advantage over hemo-
clips monotherapy.
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Apstrakt
Uvod/Cilj. Krvarenje iz peptiÿkog ulkusa može se efikasno i
bezbedno leÿiti endoskopskom terapijom hemoklipsevima.
Ipak, zbog odreĀenih ograniÿavajuýih faktora primene hemo-
klipseva možda bi kombinacija hemoklipseva sa drugom en-
doskopskom metodom dala bolje rezultate. Cilj rada bio je da
se ispita efikasnost i bezbednost endoskopske terapije hemo-
klipsevima i procene eventualne prednosti ove terapije kombi-
novane sa epinefrinom u leÿenju krvarenja iz peptiÿkog ulkusa.
Metode.  Prospektivnom, randomizovanom studijom obu-
hvaýeno je 70 bolesnika sa krvarenjem iz ulkusa želuca ili duo-
denuma. Kod 34 bolesnika  primenjena je endoskopska tera-
pija hemoklipsevima (grupa I), dok je kod 36 bolesnika prime-
njena kombinovana terapija hemoklipsevima i epinefrinom
(grupa II). Rezultati. Inicijalna hemostaza postignuta je kod
veýine bolesnika leÿenih endoskopskom terapijom hemoklip-
sevima (94.1%) i bolesnika leÿenih kombinovanom terapijom
(97.2%). Nakon postignute inicijalne hemostaze do ponovnog
krvarenja došlo je kod tri (9.3%) bolesnika tretirana hemoklip-
sevima i kod dva (5.7%) bolesnika leÿenih kombinovanom te-
rapijom, ali razlika u uÿešýu rekrvarenja nije bila statistiÿki zna-
ÿajna (p > 0,05). Razlika u postignutoj konaÿnoj hemostazi iz-
meĀu grupe I (91.1%) i grupe II bolesnika (94.4%) takoĀe nije
bila statistiÿki znaÿajna, kao ni razlika izmeĀu ispitivanih grupa
bolesnika u potrebama za transfuzijama krvi, dužini hospitali-
zacije, potrebama za hirurškom intervencijom i u mortalitetu
(p > 0,05). Zakljuÿak. Endoskopska terapija hemoklispevima
je efikasna i bezbedna za leÿenje krvarenja iz peptiÿkog ulkusa.
Kombinovana terapija hemoklipsevima i epinefrinom nema
prednosti nad monoterapijom hemoklipsevima.
Kljuÿne reÿi:
peptiÿki ulkus, krvarenje; endoskopija,
gastrointestinalna; hemostaza, endoskopska;
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Introduction
Endoscopic injection therapy is the most common
method for treating bleeding peptic ulcer. Sanation of
bleeding is achieved to a high degree using this technique,
but the recurrence of bleeding is present in 6%–36% of
cases
 1–3. If rebleeding as an important factor of mortality as
reduced, one might expect a potential reduction in mortality.
It can be difficult to achieve permanent thrombosis of blood
vessels in cases of bleeding in jet injections of epinephrine.
The application of hemoclips would theoretically be the op-
timum method in case of visible blood vessels. Hemostasis
can be definite if the vessel is adequately ligated by clips
 4, 5.
Recent data indicate that the application of endoscopic
clips is efficient and safe, than sclerosing and thermal meth-
ods, with minor damage to the surrounding tissue, and with a
smaller share of rebleeding. Therefore, their application is
being increased
 6. However, there are certain limitations in
hemoclips applications. In fact, it is difficult to place clips in
case of massive bleeding that covers the field of visualization
of the lesion or bleeding in case of tangential approach to the
lesion. Hemoclips, in combination with other methods such
as epinephrine injection, would perhaps show better results.
There are scarce literature records on the results of compari-
son of efficacy of endoscopic hemoclips therapy and a com-
bined hemoclips therapy with epinephrine
 7.
The aim of this study was to examine the efficacy and
safety of endoscopic hemoclips therapy and evaluate poten-
tial benefits of hemoclips therapy combined with epinephrine
in treatment of bleeding peptic ulcers.
Methods
This prospective randomized study included 70 patients
(47 men and 23 women) hospitalized in the Department of
Gastroenterology and Surgery because of acute bleeding
from peptic ulcer (hematemesis and/or melena).
All the patients were asked to consent for upper gas-
trointestinal endoscopy, which was done mostly within 24 h
of hospitalization. Endoscopy was performed under local
oropharyngeal anesthesia with lidocaine. Bleeding from gas-
tric or duodenal ulcer was diagnosed after endoscopy. The
patients were divided into two groups depending on the ap-
plied type of endoscopic hemostasis: group I that included 34
patients (23 males and 11 females), average age 60.3 ± 11.19
years (from 29 to 83 years) with endoscopic therapy using
hemoclips, and group II with 36 patients (24 males and 12
females), average age 62.3 ± 12.21 years (from 30 to 85
years) with combined therapy of hemoclips and epinephrine.
The examined groups of patients did not differ signifi-
cantly according to sex, age, use of nonsteroidal anti-
inflammatory drugs (NSAIDs), participation of comorbidity,
hemoglobin initial values, the localization of the ulcer, ulcer
size and affiliation to a certain Forrest group of bleeding ulcer
(Table 1). Anamnestic data were obtained by using NSAIDs, in
61.7% patients of the group I and in 61.1% of the group II.
NSAIDs diclofenac, nimesulide, indomethacin antiagregation
agents, acetylsalicylic acid and less clopidogrel were used.
From other diseases, which were present in 50% of the patients
of the group I and 52.7% of the group II, were the conditions
after myocardial infarction and stent, angina pectoris, hyperten-
sion, conditions after stroke, chronic renal failure and chronic
obstructive pulmonary disease. The average size of bleeding
ulcers in the patients of the group I was 12.6 ± 3.98 mm (7–19
mm) and of the group II 13.1 ± 4.12 mm (8–20 mm). Forrest's
classification
 8 was used for the classification of bleeding peptic
ulcers. The study involved patients with active bleeding in the
jet (Forrest Ia), flowing venous bleeding (Forrest Ib) and visible
denuded blood vessel without active bleeding (Forrest IIa). The
most common, in both groups of patients, was flowing venous
bleeding from the ulcer (Forrest Ib).
The criteria for excluding patients from the study were:
pregnancy, multiple, other, non-ulcus causes of bleeding in
the upper gastrointestinal tract, gastric malignancy, the co-
existence of acute severe disease, such as septic shock, acute
cerebrovascular incident, acute surgical abdomen, systemic
condition of increased susceptibility to bleeding – low blood
platelet counts below 50,000/mm
3, prolonged prothrombin
time with international normalized ratio (INR) over 2 and
treatment with anticoagulant drugs.
Table 1
Clinical and endoscopic characteristics of the study groups of patients
Parameter Hemoclips therapy
(n = 34)
Combination therapy
(n = 36)
p
Male/female, n 23/11 24/12 0.867
Age (years), ʉ ± SD 60.3 ± 11.19 62.3 ± 12.21 0.704
NSAID use, n (%) 21 (61.7) 22 (61.1) 0.849
Comorbid diseases, n (%) 17 (50) 19 (52.7) 0.994
Hb level (g/dL), ʉ ± SD 7.2 ± 1.4 6.9 ± 1.3 0.914
Stomach ulcer, n (%) 16 (47) 17 (47.2) 0.821
Duodenal ulcer, n (%) 18 (52.9) 19 (52.7) 0.821
Ulcer size (mm), ʉ ± SD 12.6 ± 3.98 13.1 ± 4.12 0.508
Forrest group Ia, n (%) 2 (5.9) 5 (13.9) 0.429
Forrest group Ib, n (%) 30 (88.2) 28 (77.8) 0.399
Forrest group IIa, n (%) 2 (5.9) 3 (8.3) 1.000
ʉ – mean value; SD – standard deviation; NSAID – nonsteroidal antiflamatory drug; Hb – hemoglobin
Forrest Ia – active bleeding in the jet; Forrest Ib – flowing venous bleeding; Forrest IIa – visible denuded blood vessels without active bleedingStrana 826 VOJNOSANITETSKI PREGLED Volumen 70, Broj 9
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Hemoclips endoscopic therapy was applied in the group
I of the patients with bleeding from peptic ulcer. We used EZ
clips of stainless steel material and standard ones curved at
the top at the angle of 135° (HX-610-135) and a longer
curved at the angle of 90° (HX-610-090L). Clips were placed
with the applicator through the accessible channel of 2.8 mm
in diameter of standard endoscopes.
The combined hemoclips and epinephrine therapy was
applied in the group II of the patients with bleeding from
peptic ulcer. The same clips were used as in the group I. Epi-
nephrine diluted in physiological salt solution of 1:10,000
was applied. A standard injection needle was used for appli-
cation, 23 gauge size, the length of the needles 4 mm. Basi-
cally, the first placed were clips (in 25 patients or 69.4%) in
a visible bleeding place, immediately after diluted epineph-
rine was applied, fractionally from 0.5–2 mL in four quad-
rants around the ulcer at the distance of 2–3 mm and only the
bleeding site. The injection was repeated in each quadrant
until the mucosa turned to whitish color and until hemostasis
was established. In case of more massive bleeding (in 11 pa-
tients or 30.5%), when it was not possible to see clearly the
bleeding site, the diluted epinephrine was applied immedi-
ately after the clip to achieve the reduction of bleeding.
Initial hemostasis was considered successful in case of
endoscopically verified cessation of bleeding for at least 5
min after the first endoscopic treatment
 7. In case of contin-
ued bleeding, despite endoscopic treatment, urgent surgery is
recommended.
Vital functions were monitored in all the patients, while
control of bleeding was performed using nasogastric tube
drainage. The treatment included partial parenteral nutrition
and the use of proton pump inhibitors (PPIs) in the form of
intravenous bolus of 80 mg and then infusion of 8 mg/h
during 72 h, followed by oral application of PPIs. In case of
hemoglobin (Hb) fall below 7 g/dL, a continuation of hema-
temesis and/or melena, increased heart rate to more than 100
betas per minute or systolic blood pressure fall to less than
100 mmHg, red blood cell transfusions were prescribed.
By recurrent bleeding, we meant the appearance of new
hematemesis and/or melena after initial hemostasis, the
emergency of fresh blood nasogastric tube aspiration and in-
creasing heart rate over 100 beats per minute with systolic
pressure drop over 30 mmHg, as well as a new decline in Hb
of at least 2g/dL
 7. Reapplied upper gastrointestinal endos-
copy and secondary endoscopic clips hemostasis or clips
with epinephrine was used in case of suspicion of recurrent
bleeding. Urgent surgery was recommended in case of sec-
ondary endoscopic hemostasis failure.
By final hemostasis, we meant the absence of recurrent
bleeding 7 days after initial or secondary endoscopic hemo-
stasis. All the patients were clinically followed for 8 weeks
after initial endoscopy.
Statistical analysis was performed using descriptive
statistics such as measures of central tendency [average
value, (ʉ)] and measures of dispersion [standard deviation
(SD)]. Statistical analysis methods that were used in assess-
ing the significance of difference were Student's t-test, Man-
tel-Haenszel's Ȥ
2 test with Yates's correction and Fisher's ex-
act probability test of the null hypothesis. A statistically sig-
nificant differences between individual characteristics were
considered for p < 0.05.
Results
Initial hemostasis was achieved in most of the patients
treated with endoscopic hemoclips therapy (32/34 or 94.1%)
and the patients treated with combination hemoclips and epi-
nephrine therapy (35/36 or 97.2%). The difference in the
success of initial hemostasis was not statistically significant
(p > 0.05).
Rebleeding occurred in 3 (9.3%) patients treated with
endoscopic clips therapy and 2 (5.7%) patients treated with
combination therapy of clips and epinephrine, after achieving
initial hemostasis. However, the difference in the participa-
tion of rebleeding was not statistically significant (p > 0.05).
Also, the difference in the achieved final hemostasis between
the patients treated with clips (91.1%) and the patients
treated with combination therapy (94.4%) was not statisti-
cally significant (p > 0.05).
The amount of epinephrine administered in the patients
treated with combination therapy of clips and epinephrine,
was 11.2 ± 4.56 mL (4–20 mL). The average number of
placed clips was slightly higher in the patients treated with
clips monotherapy (1.7 ± 0.49, the minimum of 1 and the
maximum of 4 clips on bleeding ulcer) than in the patients
treated with combination therapy (1.5 ± 0.68, at least 1 clip
at the maximum of 3 clips on bleeding ulcer), but the differ-
ence was not statistically significant (p > 0.05). We had dif-
ficulties with placement the clips in 3 patients of the group I
and 5 patients of the group II, with ulcer on the posterior
wall of the stomach, as well as with ulcer in the duodenal
bulb of fibrotic characteristics. Five clips fell off in 3 patients
of the group I and 8 clips in 5 patients of the group II. How-
ever, replacement of clips was successful. Unsuccessfully
placed clips were not counted in the number of clips used to
control bleeding.
There were no complications after clips treatment and
after combined therapy of clips and epinephrine in the ex-
amined groups of patients.
An average of 4.3 ± 1.58 units of blood (from 0 to 9
units) was prescribed to the patients treated with hemoclips.
An average of 3.9 ± 1.82 units of blood (from 0 to 8 units)
was prescribed to patients whose ulcers were treated with
combination therapy. The difference in the number of units
of given red blood cell concentrate between the two groups
of patients was not statistically significant (p > 0.05).
The average length of hospitalization of the group I pa-
tients was 9.2 ± 4.54 days (from 4 to 16 days), and of the
group II patients 8.9 ± 4.32 days (from 3 to 14 days). The
difference in the length of hospitalization was not statisti-
cally significant (p > 0.05).
One (2.9%) patient, in the group I patients was operated
on for recurrent ulcer bleeding on the posterior wall of sub-
cardial area of gastric corpus and secondary failure of endo-
scopic hemostasis. In the remaining 2 of 3 patients, treated
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successful secondary endoscopic hemostasis was achieved.
In the group treated with combination therapy of epinephrine
and hemoclips, 1 (2.7%) patient underwent surgery with re-
current bleeding from duodenal ulcer after the failure of sec-
ondary endoscopic hemostasis. A successful secondary en-
doscopic hemostasis was achieved in another patient with
rebleeding from ulcer. The difference in the number of oper-
ated patients between the groups was not statistically signifi-
cant (p > 0.05).
Death occurred in 2 (5.8%) patients, in the group
treated with hemoclips, with bleeding from ulcer of the
stomach corpus and duodenal ulcer after failure of initial
hemostasis, continuing bleeding and development of irre-
versible hemorrhagic shock. Death occurred in 1 (2.7%) pa-
tient, in the group treated with combination therapy, with se-
vere bleeding from the stomach ulcer and the inability of es-
tablishing initial hemostasis. The presence of significant
comorbidity such as angina pectoris, chronic obstructive
pulmonary disease or renal insufficiency was established in
cases of death in both groups of patients. The difference in
mortality was not statistically significant between the two
groups of patients (Table 2).
Discussion
Epinephrine monotherapy is considered to be subopti-
mal due to the high participation of rebleeding
 9–11. Thermal
methods such as electrocoagulation, photocoagulation and
argon plasma coagulation were effective but the potential
damage to tissues is possible
 1, 12, 13.
Hemoclips are new therapeutic alternatives with the ef-
fect identical to surgical ligature. The advantages of hemo-
clips application are direct application on the blood vessel,
no damage to bleeding lesion, no limit to the number of ap-
plied clips, interventions can be repeated and in case of fail-
ure of hemostasis they are a useful marker for radiologists in
the application of transcatheter embolization
 14. Due to the
existence of some limiting factors of hemoclips applications
such as chronic ulcer with a fibrous base, precise identifica-
tion of bleeding lesion and lesion location, we wanted to ex-
amine whether application of combined methods of hemo-
clips and epinephrine could give better results.
There was no significant difference in the two exam-
ined groups of patients, regarding the success of initial he-
mostasis achieved to a high percentage in both groups. The
difference in the participation of rebleeding was not statisti-
cally significant. Also, there was no statistically significant
difference in achieving final hemostasis in bleeding ulcers,
need for blood transfusions, length of hospitalization, needs
for surgery and mortality.
According to the results of most studies, combined
hemoclips therapy with other agents, such as epinephrine or
absolute alcohol has an advantage over epinephrine mono-
therapy or absolute alcohol in terms of rebleeding, need for
surgery and in some cases in terms of mortality
 15, 16. How-
ever, there have been a few studies dealing with compara-
tive analysis of hemoclips efficiency and hemoclips com-
bined with other hemostatic agent. One study investigated
the clips effectiveness with clips combined with absolute
alcohol 
17, while the other study investigated the clips ef-
fectiveness with clips combined with epinephrine 
18. The
results of both studies, similar to our results, showed no
statistically significant difference in the participation of
rebleeding, need for surgery and mortality. Therefore, the
combined treatment is not favored in comparison with clips
monotherapy.
In the group of patients treated with combination ther-
apy, clips were first placed in a visible bleeding place and
immediately after it diluted epinephrine was applied. In case
of more massive bleeding, when it was not possible to see
clearly the bleeding site, diluted epinephrine was first ap-
plied to achieve the reduction of bleeding and immediately
after that clips were used. Theoretically, local injection ther-
apy applied before placing clips can lead to tissue edema,
and there can appear difficulties in placing a blood vessel
clip. Gevers et al.
 19 first applied epinephrine in all patients
and then clips. They showed that the combined therapy of
epinephrine and clips was even less efficient in comparison
with the epinephrine monotherapy. The study of Lo et al. 
4
had an identical approach to epinephrine and hemoclips, as
in this study injection. They compared combined hemoclips
and epinephrine therapy with epinephrine monotherapy,
showing the superiority of combination therapy.
Table 2
Treatment results in the compared groups of patients
Parameter Hemoclips therapy
(n = 34)
Combination therapy
(n = 36)
p
Initial hemostasis, n (%) 32 (94.1) 35 (97.2) 0.608
Recurrent bleeding, n (%) 3/32 (9.3) 2/35 (5.7) 0.663
Final hemostasis, n (%) 31 (91.1) 34 (94.4) 0.669
Amount of epinephrine administered
(mL), ʉ ± SD
0 11.2 ± 4.56
Number of hemoclips applied, ʉ ± SD 1.7 ± 0.49 1.5 ± 0.68 1.397
Transfusion requirement
(number of units), ʉ ± SD
4.3 ± 1.58 3.9 ± 1.82 0.969
Hospital stay (days), ʉ ± SD 9.2 ± 4.54 8.9 ± 4.32 0.278
Surgery, n (%) 1 (2.9) 1 (2.7) 1.000
Mortality, n (%) 2 (5.8) 1 (2.7) 0.608
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According to some authors, a higher volume of epi-
nephrine, such as 13–20 mL or even 35–45 mL, can be sig-
nificantly more effective in achieving hemostasis, reducing
the need for urgent surgery, reducing hospitalization time
and mortality. The higher amount of applied epinephrine
proved to be safe, not leading to the occurrence of cardiac ar-
rhythmias
 20, 21.
The size of ulcers and the presence of active bleeding
from ulcers, as well as Forrest I bleeding lesions, could have
an impact on the success of endoscopic hemostasis. It is dif-
ficult to achieve hemostasis with larger ulcers over 20 mm 
22.
There was no statistically significant difference in the size of
ulcer, and all ulcers were less than 20 mm in both groups of
patients. Also, there was no statistically significant differ-
ence between the two groups of patients regarding the
Forrest group of bleeding ulcers. Therefore, it can be con-
cluded that for the success of endoscopic hemostasis, the
kind of therapy (hemoclips or hemoclips with epinephrine)
was responsible first, while the size of ulcer bleeding and the
Forrest group had no effect in our examines.
Addition of epinephrine to clips had no significant ef-
fect on reducing the average number of clips placed on
bleeding ulcers in our patients. Specifically, the average
number of placed clips was ranked slightly higher in the pa-
tients treated with monotherapy clips than in the patients
treated with combination therapy, but the difference was not
statistically significant. We had difficulties in placing clips in
ulcers of fibrous characteristics and the ulcers localized sub-
cardially on the back wall of the stomach. Five clips fell off
in 3 patients of the group I and 8 clips in 5 patients of the
group II. However, replacement of clips was successful.
Similar data were presented by Lo et al. 
4 who had failed at
placing 6 clips in 4 patients. According to some authors 
14, 17,
implementation of a transparent cylinder on top of an endo-
scope could help or the use of endoscopes with optics side in
cases of difficult access to a lesion such as subcardial region.
We prescribed PPIs to all the patients parenterally
within 72 h and then orally, before endoscopic intervention
and/or immediately after the initial endoscopic hemostasis
was achieved. It was proven that a significant suppression of
acid secretion with PPIs improves the success of endoscopic
hemostasis while the benefit is missing when applying H2
receptor antagonists. Achieving pH values above 6 in the
stomach, under the influence of IPPs makes stabilization of
blood clot possible
 23–25.
Complications after endoscopic clips therapy and epi-
nephrine injection therapy are rare. We have to be cautious
with deeper ulcerations due to the possibility of perforation
in applying clips. Also, it is possible to cause formation of
active bleeding in the lesions that are not actively bleeding,
such as a visible vessel or clot in the ulcer
 14. Epinephrine is
considered to be the safest of injectable agents that are used
in repair of bleeding from peptic ulcers. The possibility of
cardiac arrhythmia is described, but as a very rare complica-
tion
 2 . There were no complications following endoscopic
application of clips and application of clips with epinephrine
in the studied patients.
Conclusion
This study showed that endoscopic hemoclip therapy is
efficient and safe in treatment of bleeding peptic ulcers.
Combination therapy of hemoclips and epinephrine has no
advantage over hemoclips monotherapy. Therefore, the com-
bination therapy is not currently recommended until obtain-
ing the eventual more relevant data from larger studies.
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